GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » Price-to-Owner-Earnings

NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Price-to-Owner-Earnings : (As of Apr. 25, 2024)


View and export this data going back to 2007. Start your Free Trial

What is NovaBay Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-04-25), NovaBay Pharmaceuticals's share price is $0.0752. NovaBay Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for NovaBay Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of NovaBay Pharmaceuticals was 412.59. The lowest was 0.00. And the median was 304.20.


NBY's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.115
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-25), NovaBay Pharmaceuticals's share price is $0.0752. NovaBay Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.31. Therefore, NovaBay Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-04-25), NovaBay Pharmaceuticals's share price is $0.0752. NovaBay Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.16. Therefore, NovaBay Pharmaceuticals's PE Ratio without NRI for today is At Loss.

During the past 13 years, NovaBay Pharmaceuticals's highest PE Ratio without NRI was 73.67. The lowest was 0.00. And the median was 66.60.


NovaBay Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for NovaBay Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovaBay Pharmaceuticals Price-to-Owner-Earnings Chart

NovaBay Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NovaBay Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NovaBay Pharmaceuticals's Price-to-Owner-Earnings

For the Biotechnology subindustry, NovaBay Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovaBay Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where NovaBay Pharmaceuticals's Price-to-Owner-Earnings falls into.



NovaBay Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

NovaBay Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0752/-0.78
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovaBay Pharmaceuticals  (AMEX:NBY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


NovaBay Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Executives
Tommy Law officer: Interim CFO 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin officer: President, DERMAdoctor, LLC 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin officer: Chief Product Officer 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall officer: General Counsel 5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng director NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov director 2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones officer: CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu director SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu 10 percent owner LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Wang Xu officer: NEO - Sr Mgr and Controller 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Swan Sit director 95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng director 1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang director 2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh officer: Interim CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd 10 percent owner FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000